அதர் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: 1st Quarter Results
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global pharmaceutical drugs and biologics logistics market as it emerges from the COVID -19 shut down.
The global pharmaceutical drugs and biologics logistics market reached a value of nearly $90,300.0 million in 2020, having increased at a compound annual growth rate (CAGR) of 4.1% since 2015. The market is expected to reach $102,899.4 million by 2025, and $130,037.9 million by 2030.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 14+ geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results
News provided by
Share this article
Share this article
NEWARK, N.J., March 17, 2021 /PRNewswire/ Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021.
Q2 FY 2021 Consolidated Financial and Operational Highlights
Revenue of $1.0 million, generated by Rafael Holdings real estate portfolio, decreased from $1.2 million in the year-ago quarter due, in part, to the sale of its building in Piscataway, NJ.
Loss per share of $0.50 compared to a loss per share of $0.08 in the year ago quarter primarily due to a $7.0 million impairment of the company s interest in Altira, as described below.
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER Highlights
Strong sales performance from key growth drivers in HIV, Respiratory, Oncology and Consumer Healthcare offset disruption from COVID-19 to adult vaccinations · Pharmaceuticals £17 billion -3% AER, -1% CER; new and specialty products £9.7 billion +11% AER, +12% CER · · · New Biopharma product portfolio strengthened with 9 approvals in 2020 and Cabenuva in the US in January 2021
Effective cost control supports delivery of adjusted earnings per share in line with FY 2020 guidance · · ·
Significant progress on Biopharma pipeline with over 20 assets now in late-stage clinical trials
vimarsana © 2020. All Rights Reserved.